CompletedNCT00206128
Switching from immediate-release to extended-release quetiapine for schizophrenia
About this title
Read the official source — NCT00206128Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Birmingham and 68 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 454
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00206128
- Official title
Show the full official title
6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Anaheim, United States · Cerritos, United States
65 more locations
- Garden Grove, United States
- National City, United States
- Pasadena, United States
- San Diego, United States
- Santa Ana, United States
- North Miami, United States
- Atlanta, United States
- Hoffman Estates, United States
- New Orleans, United States
- Jackson, United States
- Clementon, United States
- Staten Island, United States
- Austin, United States
- Houston, United States
- Richmond, United States
- QLD, Australia
- Burgas, Bulgaria
- Radnevo, Bulgaria
- Varna, Bulgaria
- Vancouver, Canada
- Aurora, Canada
- Burlington, Canada
- Mississauga, Canada
- Orléans, Canada
- Toronto, Canada
- Québec, Canada
- Sherbrooke, Canada
- Prince Albert, Canada
- Põltsamaa, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Helsinki, Finland
- Mikkeli, Finland
- Turku, Finland
- München, Germany
- Göttingen, Germany
- Aachen, Germany
- Jena, Germany
- Halle, Germany
- Marburg, Germany
- Budapest, Hungary
- Debrecen, Hungary
- Gyula, Hungary
- Nagykálló, Hungary
- Szeged, Hungary
- Székesfehérvár, Hungary
- Bologna, Italy
- Cagliari, Italy
- Città di Castello, Italy
- Ellera Di Corciano, Italy
- Torino, Italy
- Bassano del Grappa, Italy
- Quartu Sant'Elena, Italy
- Riga, Latvia
- Sigulda, Latvia
- Ziegzdrai, Lithuania
- Klapeda, Lithuania
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Jerez de la Frontera, Spain
- Alcobendas, Spain
- Colmenar Viejo, Spain
- Madrid, Spain
- Móstoles, Spain
- Villamartín, Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Seroquel SR.
Who was this study for?
Listed age limits: 18 years to 65 years.
